About Josephine Li, MD
Dr. Li is an endocrinologist in the Diabetes Unit at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. She received her medical degree from Duke University School of Medicine. She completed a residency in internal medicine at Beth Israel Deaconess Medical Center in Boston and her endocrinology fellowship at Massachusetts General Hospital.
Dr. Li specializes in treating endocrine disorders with a focus on diabetes. She conducts research on how treatment response to medications for type 2 diabetes differs by genetics, with the goal of improving care for patients and advancing precision medicine.
Clinical Interests:
- Diabetes management
- Endocrinology
- Genetics
Treats:
- Adult
Languages:
- Mandarin Chinese
Locations
Mass General Endocrinology: Diabetes Clinical Center
50 Staniford St.
Suite 340
Boston, MA 02114
Phone: 617-726-8722
Medical Education
- MD, Duke University School of Medicine
- Residency, Beth Israel Deaconess Medical Center
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Endocrinology, Diabetes and Metabolism, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Josephine Li, M.D. is an Assistant Professor of Medicine at Harvard Medical School and Director of the Diabetes Clinical Center. Dr. Li?s research interests are in the pharmacogenetics of type 2 diabetes, with the goal of generating evidence to support the use of genetic information in treatment decision-making. She has completed several studies examining how genetic variation influences the glycemic response to glucose-lowering by leveraging data from clinical trials and from human physiological studies. She is the current Principal Investigator of the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH) and is leading pharmacogenetic studies in the GRADE clinical trial. More recently, she has an NIDDK-funded grant to study the pharmacogenetics of GLP-1 receptor agonists using electronic health record-linked biobanks. Supplementing this work, she is the Principal Investigator of a study examining the response to an acute oral semaglutide challenge. She is working to understand how the glycemic and metabolic effects of these medications and impact on downstream complications differ by genetics, with the overarching goal of improving care to patients and advancing precision medicine in type 2 diabetes.